Omeros Corp. (Nasdaq: OMER) announced additional positive
data from a Phase 2 clinical trial of OMS721 to treat thrombotic
microangiopathies. Shares of the biopharmaceutical leaped $9.45 to $24.00.
Positive data for Omeros
August 18, 2015 at 13:48 PM EDT
